Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Depreciation & Amortization (CF) (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $460000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 5.15% to $460000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, down 6.46% year-over-year, with the annual reading at $1.1 million for FY2025, 8.33% down from the prior year.
  • Depreciation & Amortization (CF) hit $460000.0 in Q4 2025 for Ironwood Pharmaceuticals, down from $475000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $513000.0 in Q1 2024 to a low of $270000.0 in Q2 2023.
  • Historically, Depreciation & Amortization (CF) has averaged $420400.0 across 5 years, with a median of $435000.0 in 2021.
  • Biggest five-year swings in Depreciation & Amortization (CF): tumbled 80.34% in 2021 and later surged 87.41% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $359000.0 in 2021, then fell by 5.29% to $340000.0 in 2022, then surged by 50.59% to $512000.0 in 2023, then decreased by 5.27% to $485000.0 in 2024, then dropped by 5.15% to $460000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for IRWD at $460000.0 in Q4 2025, $475000.0 in Q3 2025, and $467000.0 in Q2 2025.